Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAN IN PLASTIC CONTAINER versus CEFPROZIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAN IN PLASTIC CONTAINER versus CEFPROZIL.
CEFOTAN IN PLASTIC CONTAINER vs CEFPROZIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and cross-linking of peptidoglycan. It has broad-spectrum activity against gram-negative and gram-positive bacteria, including anaerobes, and is resistant to beta-lactamases.
Cefprozil, a second-generation cephalosporin, exerts bactericidal activity by binding to penicillin-binding proteins (PBPs) and inhibiting bacterial cell wall synthesis, leading to cell lysis.
1 to 2 g intravenously or intramuscularly every 12 hours for 5 to 10 days. Maximum dose 6 g daily.
250-500 mg orally every 12 hours for 10 days; for pharyngitis/tonsillitis: 500 mg orally every 24 hours for 10 days.
None Documented
None Documented
Clinical Note
moderateCefprozil + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefprozil."
2.8-3.2 hours in normal renal function; prolonged to 12-30 hours in severe renal impairment (CrCl <10 mL/min).
1.2-1.4 hours in adults with normal renal function; prolonged to 5-6 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (76-85% unchanged in urine via glomerular filtration and tubular secretion); biliary excretion accounts for <10%, with small amounts in feces.
Renal (primarily), approximately 60-70% unchanged in urine; biliary/fecal excretion accounts for <10%.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic